Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies

BACKGROUND: Interstitial lymphocytic lung disease (ILLD), a recently recognized complication of primary immunodeficiencies (PID), is caused by immune dysregulation, abnormal bronchus-associated lymphoid tissue (BALT) hyperplasia, with subsequent progressive loss of pulmonary function. Various modes...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodina, Yulia, Deripapa, E., Shvets, O., Mukhina, A., Roppelt, A., Yuhacheva, D., Laberko, A., Burlakov, V., Abramov, D., Tereshchenko, G., Novichkova, G., Shcherbina, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458825/
https://www.ncbi.nlm.nih.gov/pubmed/34566961
http://dx.doi.org/10.3389/fimmu.2021.704261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458825/
https://www.ncbi.nlm.nih.gov/pubmed/34566961
http://dx.doi.org/10.3389/fimmu.2021.704261

Ejemplares similares